Clinical trial NCT04052841: Morphological Analysis of Meibomian Glands
Official title: Automated Morphological Analysis of Meibomian Glands
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Meibomian Gland Dysfunction
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2019-08-12
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The recruitment of subjects must meet the diagnosis criteria of MGD the international workshop on meibomian gland dysfunction.
Primary purpose: TREATMENT

Brief summary: An automated quantitative meibomian gland analyzer based on all kinds of infrared meibomian gland images was develop to obtain more detail in meibomian gland, including width, length, area, signal intensity correlated to the quality of meibum, deformation index and ratio of area of each visible specific gland. The purpose of this study is present as separate sections the following points: (1) to compared the detailed characteristics of meibomian glands in normal subjects, Meibomian gland dysfunction (MGD) patients by the automated quantitative analyzer; (2) to identify the inter-examiner and intra-examiner repeatability of the new technique; (3) to explore the correlation among morphological and functional parameters of meibomian gland and risk factors，clinical symptoms and signs; (4) to explore the sensitivity and specificity of meibomian gland morphological and functional parameters in MGD diagnosis. (5) using morphological and functional parameters as new assessment of MGD severity and efficacy indicators for treatment.

Detailed description: Meibomian glands are essential for maintaining ocular surface health and integrity secrete various lipid components to forms a lipid layer to prevent excessive tear evaporation. Functional disorders of the meibomian glands, referred to today as meibomian gland dysfunction (MGD), are increasingly recognized as a high incidence disease commonly characterized by terminal duct obstruction and/or abnormal glandular secretion, often results in ocular surface epithelium damage, chronic blepharitis and dry eye disease that significantly reduces quality of life. A wide variation of the prevalence of MGD were reported from 0.39% to 69.3%, which is likely due to lack of diagnostic methods. To identify which clinical features are likely to be predictive of progressive disease in MGD may indicate the early diagnosis and proper treatment strategies.

Histologic section through the normal meibomian glands and the obstructed human meibomian gland revealed that obstruction of orifice in MGD could lead to dilation of the central duct, damage of the secretory meibocytes and finally result in atrophy of dilated meibomian glands and glands drop-out. It was thus be accepted that detailed changes of meibomian glands morphology are key signs to diagnose and evaluate the severity of MGD. The detailed changes including dilation, distortion, shortening and loss of visualisation of glands which can be directly observed and visual assessment by the developed of non-contact meibomian gland infrared imaging technology. Quantitative evaluations of meibomian glands were obtain by developing imaging processing techniques. The most common use is the image editing software Image J (National Institute of Health; http://imagej.nih.gov/ij) which can identify the gland region on the image manually by the users and may lead to inter-observer variability. Koh et al., first applied original algorithms to automatically analysed gland loss in meibography images with a manually pre-processing. Reiko et al., then develop an objective and automatic system to measure the meibomian gland area. However, the existing methods of meibomian gland analysis have been limited to clinical use where large number of images needs to be analyzed efficiently due to the inter-observer variability or time-consuming process.

Meanwhile, the existing quantitative morphological parameters obtain by those imaging processing techniques, including percentage of MG drop-out and gland atrophy area, were suggested to not only be advanced stages or terminal changes in MGD, but also occurs as an age-related atrophic process. The early findings of MGD induced by the primary pathologic obstruction including degenerative gland dilation, irregularly shapes of gland and change of meibum quality are still difficult to be evaluated automatically and quantitively from the image. Moreover, the meibomian gland drop-out is still an approximate assessment without specific pattern. Whether the atrophy or loss occur in upper or lower eyelids, central, distal or proximal, total loss of gland or partial loss of gland has the greatest effect on the pathology progress of MGD will be important to identify. Thus, a comprehensive analysis technique to automatically detect multi-information of meibomian gland morphology will benefit the future early diagnosis and management of MGD.

Recently, an automated quantitative meibomian gland analyzer based on all kinds of infrared meibomian gland images was develop to obtain more detail in meibomian gland, including width, length, area, signal intensity correlated to the quality of meibum, deformation index and ratio of area of each visible specific gland. The purpose of this study is present as separate sections the following points: (1) to compared the detailed characteristics of meibomian glands in normal subjects and MGD patients by the automated quantitative analyzer; (2) to identify the inter-examiner and intra-examiner repeatability of the new technique; (3) to explore the correlation among morphological and functional parameters of meibomian gland and risk factors，clinical symptoms and signs; (4) to explore the sensitivity and specificity of meibomian gland morphological and functional parameters in MGD diagnosis. (5) using morphological and functional parameters as new assessment of MGD severity and efficacy indicators for treatment.

Eligibility criteria: General Inclusion Criteria:

* Age from 18 to 70 years.
* Patients and healthy volunteers who are willing and capable to participate in this clinical study with signed Informed Consent Form.

Inclusion Criteria of patients:

* Clinical diagnosis of MGD: The diagnosis of MGD was based on an altered quality of expressed secretions and/or decreased or absent expression.
* Patients without ≥2/3 Meibomian glands atrophy.
* Fitzpatrick skin type 1-4.

Inclusion Criteria of healthy volunteers:

* Negative history or condition of ocular or systemic illness based on evaluation by a research physician.

General Exclusion Criteria:

* Patients and healthy volunteers with ocular allergies, trauma, contact lens wear, continuous medications usage such as tretinoin, isotretinoin, antidepressant medications, photosensitive drugs, glucocorticoids and immunomodulators, or have used them within one month.
* Patients and healthy volunteers who have a history of ocular surface surgery.
* Patients and healthy volunteers who have active ocular surface infection or have suffered from ocular surface infection within one month.
* Patients and healthy volunteers who have endophthalmitis or a medical history of endophthalmitis.
* Patients and healthy volunteers who have a medical history of viral keratitis infection.
* Women who are pregnant, planning to become pregnant during the course of the study or breast-feeding (women of child-bearing age will be asked by the physician).
* Meibography images were blurred or with obvious tarsus folds, incomplete exposure and large hyperreflective area.
* Patients and healthy volunteers who are not suitable for the trial as determined by investigators.

Exclusion Criteria of patients:

* Patients have abnormalities of ocular surface function or eyelid function, or presence of precancerous lesions, cancer or pigmentation in the eyelid area.
* Patients who have plans to receive ocular surgeries (e.g., cataract, myopic refractive surgery) within 6 months.
* Patients who have been treated with lacrimal punctum embolization within one month.
* Patients with disease that could lead to ADDE, such as Sjogren syndrome and a lacrimal gland abnormality.

Primary outcomes:
measure: Mophology of meibomian glands
timeFrame: 30 days after commencement of treatment
measure: Functional feature of meibomian glands
timeFrame: 30 days after commencement of treatment
Secondary outcomes:
measure: Non-invasive tear-film break-up time
timeFrame: Baseline
measure: Non-invasive tear-film break-up time
timeFrame: 15 days after commencement of treatment
measure: Non-invasive tear-film break-up time
timeFrame: 30 days after commencement of treatment
measure: Non-invasive tear-film break-up time
timeFrame: 90 days after commencement of treatment
measure: Non-invasive tear-film break-up time
timeFrame: 180 days after commencement of treatment
measure: Non-invasive tear meniscus height
timeFrame: Baseline
measure: Non-invasive tear meniscus height
timeFrame: 15 days after commencement of treatment
measure: Non-invasive tear meniscus height
timeFrame: 30 days after commencement of treatment
measure: Non-invasive tear meniscus height
timeFrame: 90 days after commencement of treatment
measure: Non-invasive tear meniscus height
timeFrame: 180 days after commencement of treatment
measure: Tear film lipid layer thicknesses
timeFrame: Baseline
measure: Tear film lipid layer thicknesses
timeFrame: 15 days after commencement of treatment
measure: Tear film lipid layer thicknesses
timeFrame: 30 days after commencement of treatment
measure: Tear film lipid layer thicknesses
timeFrame: 90 days after commencement of treatment
measure: Tear film lipid layer thicknesses
timeFrame: 180 days after commencement of treatment
measure: The pattern of eye blinks
timeFrame: Baseline
measure: The pattern of eye blinks
timeFrame: 15 days after commencement of treatment
measure: The pattern of eye blinks
timeFrame: 30 days after commencement of treatment
measure: The pattern of eye blinks
timeFrame: 90 days after commencement of treatment
measure: The pattern of eye blinks
timeFrame: 180 days after commencement of treatment
measure: Lid margin signs
timeFrame: baseline
measure: Lid margin signs
timeFrame: 15 days after commencement of treatment
measure: Lid margin signs
timeFrame: 30 days after commencement of treatment
measure: Lid margin signs
timeFrame: 90 days after commencement of treatment
measure: Lid margin signs
timeFrame: 180 days after commencement of treatment
measure: Meibum expressibility
timeFrame: baseline
measure: Meibum expressibility
timeFrame: 15 days after commencement of treatment
measure: Meibum expressibility
timeFrame: 30 days after commencement of treatment
measure: Meibum expressibility
timeFrame: 90 days after commencement of treatment
measure: Meibum expressibility
timeFrame: 180 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: baseline
measure: Corneal Fluorescein Staining
timeFrame: 15 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: 30 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: 90 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: 180 days after commencement of treatment
measure: Schirmer I test
timeFrame: baseline
measure: Schirmer I test
timeFrame: 15 days after commencement of treatment
measure: Schirmer I test
timeFrame: 30 days after commencement of treatment
measure: Schirmer I test
timeFrame: 90 days after commencement of treatment
measure: Schirmer I test
timeFrame: 180 days after commencement of treatment
measure: Mophology of meibomian glands
timeFrame: 15 days after commencement of treatment
measure: Mophology of meibomian glands
timeFrame: 90 days after commencement of treatment
measure: Mophology of meibomian glands
timeFrame: 180 days after commencement of treatment
measure: Mophology of meibomian glands
timeFrame: Baseline
measure: Functional feature of meibomian glands
timeFrame: Baseline
measure: Functional feature of meibomian glands
timeFrame: 15 days after commencement of treatment
measure: Functional feature of meibomian glands
timeFrame: 90 days after commencement of treatment
measure: Functional feature of meibomian glands
timeFrame: 180 days after commencement of treatment
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-Sen University
state: Guangdong
city: Guangzhou
country: China
facility: Deng Yuqing
Study officials:
affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University
name: Jin Yuan, PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Arita R, Suehiro J, Haraguchi T, Shirakawa R, Tokoro H, Amano S. Objective image analysis of the meibomian gland area. Br J Ophthalmol. 2014 Jun;98(6):746-55. doi: 10.1136/bjophthalmol-2012-303014. Epub 2013 Jun 27.
citation: Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1930-7. doi: 10.1167/iovs.10-6997b. Print 2011 Mar. No abstract available.
citation: Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997 Dec;124(6):723-8. doi: 10.1016/s0002-9394(14)71688-5.
citation: Lekhanont K, Rojanaporn D, Chuck RS, Vongthongsri A. Prevalence of dry eye in Bangkok, Thailand. Cornea. 2006 Dec;25(10):1162-7. doi: 10.1097/01.ico.0000244875.92879.1a.
citation: Uchino M, Dogru M, Yagi Y, Goto E, Tomita M, Kon T, Saiki M, Matsumoto Y, Uchino Y, Yokoi N, Kinoshita S, Tsubota K. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci. 2006 Nov;83(11):797-802. doi: 10.1097/01.opx.0000232814.39651.fa.
citation: Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003 Jun;31(3):229-32. doi: 10.1046/j.1442-9071.2003.00634.x.
citation: Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003 Aug;136(2):318-26. doi: 10.1016/s0002-9394(03)00218-6.
citation: Wise RJ, Sobel RK, Allen RC. Meibography: A review of techniques and technologies. Saudi J Ophthalmol. 2012 Oct;26(4):349-56. doi: 10.1016/j.sjopt.2012.08.007.
citation: Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49. doi: 10.1167/iovs.10-6997f. Print 2011 Mar. No abstract available.
citation: Simcock B. The role of the intrauterine device in contraceptive practice. Aust Fam Physician. 1976 Mar;5(2):124-39.
citation: Knop E, Knop N, Brewitt H, Pleyer U, Rieck P, Seitz B, Schirra F. [Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye]. Ophthalmologe. 2009 Nov;106(11):966-79. doi: 10.1007/s00347-009-2043-9. German.
citation: Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Fukuoka S, Tomidokoro A, Amano S. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology. 2009 Nov;116(11):2058-63.e1. doi: 10.1016/j.ophtha.2009.04.037. Epub 2009 Sep 10.
citation: Koh YW, Celik T, Lee HK, Petznick A, Tong L. Detection of meibomian glands and classification of meibography images. J Biomed Opt. 2012 Aug;17(8):086008. doi: 10.1117/1.JBO.17.8.086008.
citation: Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1938-78. doi: 10.1167/iovs.10-6997c. Print 2011 Mar. No abstract available.